CD274 and non-small cell lung carcinoma: For early versus late NGS testing (Figures 10-17), there were greater odds of receiving early NGS-based testing among patients with a later year of initial NSCLC diagnosis, who had no history of smoking, who were in later drug period approval periods, had a PD-L1 test, treated in the MAC J8 WPS, and who had no other biomarker tests or inconclusive testing.